Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies
The pathophysiological changes associated with hypoestrogenism of menopause, a condition known as genitourinary syndrome of menopause, are responsible for the hallmark symptoms of vulvovaginal atrophy (VVA), namely dyspareunia secondary to vaginal dryness. Many postmenopausal women with VVA find sex...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2020-07-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/experience-with-ospemifene-in-patients-with-vulvar-and-vaginal-atrophy-and-associated-sexual-dysfunction:-case-studies/ |
| _version_ | 1818924129344028672 |
|---|---|
| author | Ana Rosa Jurado López Francisca Molero Rodríguez |
| author_facet | Ana Rosa Jurado López Francisca Molero Rodríguez |
| author_sort | Ana Rosa Jurado López |
| collection | DOAJ |
| description | The pathophysiological changes associated with hypoestrogenism of menopause, a condition known as genitourinary syndrome of menopause, are responsible for the hallmark symptoms of vulvovaginal atrophy (VVA), namely dyspareunia secondary to vaginal dryness. Many postmenopausal women with VVA find sexual relations to be challenging or impossible. Ospemifene has estrogen-like effects on the vaginal epithelium, and is indicated to treat moderate-to-severe symptomatic VVA (Europe) or moderate-to-severe symptomatic dyspareunia and vaginal dryness (United States) in postmenopausal women. The case studies presented in this article follow the progress of two women who began treatment with ospemifene for the main presenting symptom of dyspareunia. Both women had concerns about the impact of their symptomatology on new relationships. The patient in case 1 experienced relevant improvement within 3 months of treatment start and, by 1 year, dyspareunia was absent. Vaginal lubricants were no longer required. The patient in case 2 experienced relevant improvement within 4 weeks of starting ospemifene. At 15 months, with the use of a lubricant for vaginal penetration, she could enjoy sexual intercourse without pain. At the time of writing, she had been receiving ospemifene continuously for more than 2 years with effective symptom relief and good tolerability. |
| first_indexed | 2024-12-20T02:20:25Z |
| format | Article |
| id | doaj.art-0b41a62e9b81404bb165053516ef9715 |
| institution | Directory Open Access Journal |
| issn | 1740-4398 1740-4398 |
| language | English |
| last_indexed | 2024-12-20T02:20:25Z |
| publishDate | 2020-07-01 |
| publisher | BioExcel Publishing Ltd |
| record_format | Article |
| series | Drugs in Context |
| spelling | doaj.art-0b41a62e9b81404bb165053516ef97152022-12-21T19:56:50ZengBioExcel Publishing LtdDrugs in Context1740-43981740-43982020-07-0191610.7573/dic.2020-3-8Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studiesAna Rosa Jurado LópezFrancisca Molero RodríguezThe pathophysiological changes associated with hypoestrogenism of menopause, a condition known as genitourinary syndrome of menopause, are responsible for the hallmark symptoms of vulvovaginal atrophy (VVA), namely dyspareunia secondary to vaginal dryness. Many postmenopausal women with VVA find sexual relations to be challenging or impossible. Ospemifene has estrogen-like effects on the vaginal epithelium, and is indicated to treat moderate-to-severe symptomatic VVA (Europe) or moderate-to-severe symptomatic dyspareunia and vaginal dryness (United States) in postmenopausal women. The case studies presented in this article follow the progress of two women who began treatment with ospemifene for the main presenting symptom of dyspareunia. Both women had concerns about the impact of their symptomatology on new relationships. The patient in case 1 experienced relevant improvement within 3 months of treatment start and, by 1 year, dyspareunia was absent. Vaginal lubricants were no longer required. The patient in case 2 experienced relevant improvement within 4 weeks of starting ospemifene. At 15 months, with the use of a lubricant for vaginal penetration, she could enjoy sexual intercourse without pain. At the time of writing, she had been receiving ospemifene continuously for more than 2 years with effective symptom relief and good tolerability.https://www.drugsincontext.com/experience-with-ospemifene-in-patients-with-vulvar-and-vaginal-atrophy-and-associated-sexual-dysfunction:-case-studies/ospemifenesexual dysfunctionvulvar and vaginal atrophy |
| spellingShingle | Ana Rosa Jurado López Francisca Molero Rodríguez Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies Drugs in Context ospemifene sexual dysfunction vulvar and vaginal atrophy |
| title | Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies |
| title_full | Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies |
| title_fullStr | Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies |
| title_full_unstemmed | Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies |
| title_short | Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies |
| title_sort | experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction case studies |
| topic | ospemifene sexual dysfunction vulvar and vaginal atrophy |
| url | https://www.drugsincontext.com/experience-with-ospemifene-in-patients-with-vulvar-and-vaginal-atrophy-and-associated-sexual-dysfunction:-case-studies/ |
| work_keys_str_mv | AT anarosajuradolopez experiencewithospemifeneinpatientswithvulvarandvaginalatrophyandassociatedsexualdysfunctioncasestudies AT franciscamolerorodriguez experiencewithospemifeneinpatientswithvulvarandvaginalatrophyandassociatedsexualdysfunctioncasestudies |